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Abstract
Immunosuppressive functions conferred by regulatory cyto-
kines are important for maintaining homeostasis in immune
responses. IL35 has recently emerged as a novel regulator of
immune responses. Once thought to be specifically expressed by
T regulatory cells, induction of IL35 expression has now been
detected in multiple cell types in a variety of diseases, prompting
research into regulation of its expression, signaling specificity,
target cell populations, and functional outputs. Recent studies
have revealed that by directing de novo generation of regulatory
T and B cells and inhibiting T effector responses, IL35 plays an
important role in the development of autoimmune diseases
and cancer. IL35 is overexpressed in a variety of cancers and may
exert its function both on antitumor immune responses as well
as directly on tumor cells. As such, IL35 is rapidly emerging
as a promising biomarker and an attractive cancer therapy target.
Clin Cancer Res; 22(20); 4973–8. 2016 AACR.
Background
The immune system is a powerful weapon in defense against
pathogens. However, immune responses that fail to be properly
regulated can result in autoimmune conditions, and compro-
mised immune responses enable growth of cancer. A robust
system of regulatory elements has evolved to ensure homeo-
static control of immunity. These include cell contact-depen-
dent and independent mechanisms, the latter of which is
typically mediated by cytokines. Cytokines affect a broad range
of immune cell properties, including proliferation and differ-
entiation. This review will focus on the role of immunosup-
pressive cytokine IL35 in control of immune regulation and
discuss potential for targeting IL35-regulated pathways as a way
to ameliorate autoimmunity and enhance antitumor immune
responses.
IL35 is a member of the IL12 family of heterodimeric
cytokines. These cytokines form via combinations of p19,
p28, p35, p40, and Ebi3 subunits, and in addition to IL35
(p35/Ebi3) also include IL12 (p35/p40), IL23 (p19/p40),
and IL27 (p28/Ebi3; ref. 1). Members of IL12 family exhibit
mostly proinflammatory (IL12 and IL23) or mostly immu-
nosuppressive (IL27 and IL35) effector functions (1). As
proposed nearly 20 years ago by Devergne and colleagues,
IL35 itself is formed by interaction between p35 and Ebi3 (2).
However, the functional studies demonstrating immunosup-
pressive capacity of IL35 were only completed in the mid-
2000s by Vignali and colleagues (3). They found that sub-
units p35 and Ebi3 were coexpressed in Foxp3þ T cells and
that lack of either subunit reduced suppressive capacity of T
regulatory cells (Treg) in vitro and led to poor control of
inflammatory bowel disease in vivo (3). IL35 was first
reported to be produced exclusively by Tregs (3, 4). More
recent studies have demonstrated that IL35 can also be
produced by tolerogenic dendritic cells (DC; ref. 5) and B
cells (6–8). Studies reporting expression of IL35 in cancer
cells are also beginning to emerge. So far, some nonimmune
cell types, such as pancreatic cancer cells, nasopharyngeal
carcinoma, melanoma, and breast cancer cells were shown
to express IL35 (9–11). IL35 is not constitutively expressed in
normal tissues (12), and lack of developmental defects in
IL12a/ (p35 null) and Ebi3/ mice suggests that it is not
essential for normal development (13, 14). As such, expres-
sion of IL35 in immune cells appears to be induced in
conditions accompanied by underlying inflammation. For
example, IL35 expression is not detectable in na€ve T cells
or B cells, but can be triggered by inflammatory input,
impinging at least in part on Toll-like receptor stimulation
(12, 15). Our understanding of specific disease-driven phys-
iologic cues that trigger the expression of IL35 in this expand-
ing array of cell types is far from complete, and more research
needs to be done to determine the regulatory mechanisms
that affect IL35 expression in the context of inflammation and
cancer.
IL35 signaling is mediated by binding to its cognate receptor
and subsequent activation of the JAK–STAT pathway (Fig. 1).
Just as there are multiple subunits that comprise IL12 family of
cytokines, there are multiple receptor subunits (gp130,
IL12Rb1, IL12Rb2, IL23R, and IL27Ra) that can accommodate
binding of IL12 cytokine family heterodimers (1, 16). To
identify the cognate receptor for IL35, Collison and colleagues
used T cells that lacked expression of select receptor chains and
demonstrated that gp130 and IL12Rb2 expressed on T cells
were able to transduce the IL35 signal (17). Once IL35 bound
to the receptor, the signal was propagated by a heterodimer of
STAT1 and STAT4 (17). As some of the target genes of this
heterodimer included IL12a and Ebi3 themselves, STAT1:
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STAT4 signal resulted in sustained expression of IL35 via a
feed–forward loop. Intriguingly, single-chain gp130 or
IL12Rb2 receptor-deficient T cells still exhibited some degree
of response to IL35, suggesting that IL35 possesses a unique
ability to signal through homodimers of gp130 and IL12Rb2
(1, 18), engaging STAT1 or STAT4 signaling, respectively.
Either one of the combinations was sufficient to mediate
partial inhibition of T-cell proliferation; however, use of
gp130:IL12Rb2 heterodimer was required for maximal sup-
pression (17). Adding more complexity, it appears that IL35
signaling is mediated through diverse receptor chain pairings
in different immune cells. A recent report demonstrated that
IL35 activity in B cells is mediated by a heterodimer of
IL12Rb2:IL27Ra, which signals through STAT1:STAT3 (7).
Although in vivo targets of IL35 still await precise characteri-
zation, cell type-specific expression of IL35 receptor subunits
may dictate restriction of its biological activity. For example,
IL12Rb2 expression is restricted to activated DC, T cells, and
NK cells, whereas gp130 is ubiquitously expressed and may
conduct IL35 signaling in a variety of cells, including cancer
cells (19–23).
Early studies unraveled the role of IL35 in immunomodula-
tion in inflammatory disease and demonstrated functional
role for IL35 in conferring cell contact-independent T-cell
suppression. So far, the best studied mechanism of immuno-
modulatory activity of IL35 has been exemplified by induction
of Tregs and suppression of T-cell effector function and pro-
liferative capacity in a variety of in vitro and in vivo systems
(3, 24, 25). The mechanism of IL35 action on target T cells
seems to be 2-fold (Fig. 1). First, IL35 can induce cell-cycle
arrest of effector T-cell population and inhibit production of
effector cytokines (3, 24). This has also been shown in a
mouse model, where transgenic mice with IL35 overexpression
in islet cells induced cell-cycle arrest of resident T cells, leading
to reduced inflammation and a decrease in diabetes-associated
symptoms (26). Furthermore, studies performed on CD4þ
Tregs derived from IL12a/ or Ebi3/ mice demonstrated
reduced capacity of mutant Tregs to inhibit proliferation of
T effector cells (3, 27). These observations were validated using
a recombinant version of IL35 (rIL35), which led to a decrease
in cell proliferation of T effector cells (3). Although informa-
tive, experiments utilizing rIL35 need to be interpreted
carefully due to a low rate of formation of active heterodimers
of p35 and Ebi3 in preparation of rIL35 (28). Another
mechanism by which IL35 affects inflammatory microenviron-
ment is through expansion of Tregs. Proliferation of CD4þ
CD25þFoxp3 T cells was induced after exposure to IL35, which
also led to increase in IL10 expression and functional
suppression of T effector cells (29). Supporting this notion,
treatment with recombinant IL35 (rIL35) induced expansion
of tolerance-conferring CD4þCD39þFoxp3 T cells in a
model of collagen-induced arthritis (CIA) (30). Using a com-
plimentary approach, transfection of IL35-encoding vectors
into conventional na€ve CD4þFoxp3 T cells resulted in con-
version to cells with a regulatory phenotype, which were
termed iTr35 cells (15). This suppressive capacity of IL35 is
also evident in CD8þ Tregs, as they could suppress T-cell
proliferation in an IL35-dependent manner (31). In addition
to suppressing CD4þ and CD8þ T cells, expression of IL35 by T
cells has been implicated in reduced differentiation capacity of
T effector cells. For example, differentiation of Th17 effectors
from CD4þ T cells is perturbed following exposure to rIL35,
and this defect correlated with alleviated symptoms in mouse
models of Th1/Th17–driven inflammatory diseases, such as
CIA and colitis (27, 29). Supporting this notion, T cells derived
from Ebi3/ mice exhibited increased production of IL17
(32, 33).
The role of IL35 expression in cell types other than T cells is
only beginning to be elucidated (Fig. 2). A regulatory popu-
lation of B cells, termed Bregs has long been implicated in the
suppression of T cell–mediated immune responses and control
of autoimmune diseases, such as experimental autoimmune
© 2016 American Association for Cancer Research
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Figure 1.
IL35-dependent signaling pathways. When
signaling via gp130:gp130 or IL12Rb2:IL12Rb2
homodimers, IL35 inhibits proliferation of
target T and B cells. Signals transduced
through gp130:IL12Rb2 or IL27Ra:IL12Rb2
parings can confer both suppression of
proliferation and induction of specialized
regulatory cell lineages, such as Treg, iTr35,
and Bregs.
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encephalitis (EAE) and CIA (34–38). Although cell-surface
markers used to identify this cell population depend on disease
context, the unifying functional suppressive mechanism has,
for a long time, impinged on the production of IL10 (34, 39,
40). However, it was realized that Bregs may operate through a
variety of immunosuppressive mechanisms, as at least some
of the regulatory functions of Bregs can be mediated indepen-
dently of IL10 (41–43). In support of this notion, a recent study
by Wang and colleagues utilized rIL35 to induce suppressive
Bregs (7). Treatment with rIL35 also converted na€ve B cells into
Bregs that were capable of producing de novo IL35. This
IL35-mediated expansion of Bregs and Tregs occurred concur-
rently with the inhibition of T effector responses (7). Another
study documented upregulation of Ebi3 gene after stimulation
of B cells with TLR and CD40 (6). This observation led to a
series of elegant experiments, where chimeric mice, in which B
cells lacked expression of either p35 or Ebi3, exhibited exac-
erbated EAE as well as protection from infection with Salmo-
nella (6), suggesting that IL35 production by B cells controls
hyperactive immune responses. In this case, the activity of IL35
seemed to affect regulation of antigen-presenting capacity of B
cells, decreased autoimmunity, and increased clearance of
infectious agent. In addition to studies on B cells, a recent
report by Dixon and colleagues has also demonstrated
that expression of IL35 by tolerogenic DCs suppresses T-cell
activation (5).
Clinical–Translational Advances
A number of studies suggest that levels of IL35 fluctuate
in disease (16, 44). Elucidation of the precise role of IL35
in humans awaits generation of better reagents that will
not only allow for accurate detection of this cytokine, but
will enable characterization of its action outside of murine
cells and disease models. Nevertheless, substantial preclin-
ical evidence for the immunomodulatory potential of IL35
has stimulated interest in developing IL35 as a biomarker
and potential treatment target in inflammatory diseases
(Fig. 2).
As IL35 confers an important regulatory role on immune
responses, there is considerable interest in understanding
the therapeutic potential of modulating IL35 levels and
signaling in a variety of diseases. Reduction in IL35 expres-
sion has been associated with multiple inflammatory con-
ditions, such as inflammatory bowel disease, liver fibrosis,
myocarditis, encephalomyelitis, and autoimmune disease,
and correlated with severity of disease and increase in
inflammation (3, 29, 30, 45). In this case, administration
of rIL35, IL35 gene therapy, or adoptive transfer of IL35
competent cells may alleviate disease symptoms. For exam-
ple, adoptive transfer of IL35þ Tregs alleviated symptoms of
colitis, intratracheal administration of rIL35 reduced airway
inflammation in a model of allergy (46), and rIL35
decreased severity of arthritis and uveitis (7, 30). Similarly,
overexpression of IL35 protected from acute GVHD, myo-
carditis, and atherosclerosis (47–49). Genetic studies using
IL12a- and Ebi3-null mice have validated the importance of
IL35 in alleviating symptoms of autoimmune and chronic
inflammation (6).
Perhaps not surprisingly, contrary to autoimmune condi-
tions, expression of IL35 has been implicated in promoting
tumorigenesis (Table 1; refs. 8, 10, 31, 50). Elevated levels of
IL35 were detected in lymphoma cells (51) and lung cancer
and predicted poor outcome in cases of leukemia, colorectal
© 2016 American Association for Cancer Research
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Figure 2.
Proposed functional roles of IL35 in disease.
Expression of IL35 is induced in many disease
contexts under conditions of inflammation. A
few different cell types, such as Treg, Breg, and
DC, have been shown to express IL35, although
precise regulation of induction is still not clear.
In models of cancer, production of IL35 impairs
antitumor immune responses and promotes
tumorigenesis. In autoimmunity and chronic
inflammation, expression of IL35 is protective
and is postulated to subdue autoreactivity in
disease models of EAE, colitis, experimental
autoimmune uveitis and others.
Role of Suppressive Cytokine IL35 in Disease
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cancer, and pancreatic cancer (52–54). Increase in tumor-
infiltrating IL35þ T cells and Bregs has now also been
reported in melanoma, colorectal cancer, and pancreatic
cancer (8, 50). These observations suggest that inhibition
of IL35 expression or downstream signaling may suppress
tumorigenic potential. Functional experiments showed that
Ebi3-null mice have reduced metastatic burden when chal-
lenged with a melanoma cell line (55), and in a separate
study, a model of melanoma exhibited dependence on IL35
for the accumulation of MDSC and induction of angiogen-
esis (10). Using a mouse model of pancreatic cancer, we
have demonstrated that IL35þ Bregs are directly recruited to
the tumor cell vicinity via a chemokine gradient of CXCL13
and promote tumorigenesis in an IL35-dependent manner
(8). A recent elegant study by Turnis and colleagues used an
Ebi3 reporter mouse to follow the fate of IL35þ cells in
cancer development and test the effect of Ebi3 genetic
ablation specifically in the Treg cell lineage (50). Resulting
observations have implicated IL35 production by Tregs in
control of antitumor immunity (50). Using models of colon,
lung, and melanoma, this study has shown that Treg-pro-
duced IL35 regulates antigen-specific CD8þ T-cell infiltration,
T effector function and memory, as well as T-cell exhaustion.
On the basis of the known complexity of IL35 regulation and
target selection, the effects of IL35 in tumor promotion are
likely multifaceted and may impinge on controlling antitu-
mor immunity, angiogenesis, and potentially, tumor cell
proliferation directly (8, 10, 11, 50).
Conclusions/Future Directions
The regulatory potential of IL35makes it an attractive target for
therapeutic intervention. Recombinant IL35 or IL35-producing
cells can alleviate autoimmunity, while disruption of IL35 expres-
sion or signaling may reactivate antitumor immunity. There are
still many questions and challenges that need to be resolved
before the field is able to move forward. Generation of robust
reagents for studies of IL35 in human systems will enable vali-
dation of the physiologic importance of IL35 signaling in disease.
Relevance of various cellular sources of IL35 needs to be validated
in vivo. Structural studies aimed at unmasking interactions
between IL35 and its receptors will allow us to understand the
mechanism of receptor utilization by IL35 and more readily
identify recipient cell populations. Overall, understanding the
regulation and physiologic relevance of IL35 production in vivo
will enhance our capacity to assess the value of therapeutic
utilization of IL35 in disease.
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